ClinicalTrials.gg
CompletedNCT03266133Updated Aug 12, 2019

Sleep Intervention to Improve Glycemic Control in Women With Gestational Diabetes

An interventional study of Sleep Education for Pregnancy in Gestational Diabetes Mellitus in Pregnancy, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

This is a pilot randomized controlled trial involving a sleep education intervention in women with gestational diabetes to study whether sleep education during pregnancy leads to improvement in glycemic control in women with gestational diabetes and improvement in sleep duration.

Read the detailed description

Patients will be identified from the Maternal-Fetal Medicine office and the Perinatal Assessment Clinic at Magee-Womens Hospital, University of Pittsburgh Medical Center. Patients with gestational diabetes will be recruited following general education regarding gestational diabetes in pregnancy which is universally done for all patients at the time of their diagnosis of gestational diabetes. Eligible subjects will be randomized to two groups (usual care vs. sleep education program).

02

Conditions studied

  • Gestational Diabetes Mellitus in Pregnancy

Browse trials for

Keywords

  • Gestational Diabetes Mellitus
  • Sleep education
03

In context

Diabetes, Gestational

857 studies on the registry are indexed under Diabetes, Gestational; 199 are open to participants now.

This study's enrollment of 74 is below the median of 110 across 560 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,414 studies on the registry; 168 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pregnant female
  2. Ages 18-50
  3. Gestational age between 16 0/7 weeks and 31 6/7 weeks
  4. New diagnosis of GDM, not on treatment (i.e., insulin, glyburide, or metformin) at the time of enrollment

Exclusion criteria

Exclusion Criteria:

  1. Children less than 18 years of age
  2. Non-English speaking
  3. Multiple gestations (twins, triplets, etc)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Sleep Education Intervention

    This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.

    Behavioral: Sleep Education for Pregnancy

  • No intervention
    Routine Care

    Usual care

Interventions

  • BehavioralSleep Education for Pregnancy

    Sleep education specific to pregnancy

06

What researchers measure

Primary outcomes

  1. Glycemic control

    Proportion of participants achieving glycemic control at study end. Glycemic control defined as greater than 75% of weeks with average fasting blood glucose \< 95 mg/dL and 1-hr postprandial blood glucose \<140 mg/dL.

    Time frame: 3-6 months during pregnancy

  2. Self-reported sleep duration

    Proportion of patients who report sleeping between 7-9 hours per night

    Time frame: 3-6 months during pregnancy

Secondary outcomes

  1. Average fasting glucose values

    Time frame: 3-6 months during pregnancy

  2. Average postprandial glucose values

    Time frame: 3-6 months during pregnancy

  3. Gestational age at delivery

    Time frame: Time of delivery

  4. Neonatal birth weight

    Time frame: Time of delivery

  5. Indication for delivery

    Medical records will be used to determine whether a patient when into spontaneous labor, had an induction or labor or a recommended delivery by cesarean section. If the patient had an induction or labor or a recommended cesarean delivery, the indication for this recommendation will be recorded.

    Time frame: Time of delivery

  6. Route of delivery

    Medical records will be reviewed to determine if the patient had a vaginal delivery or cesarean delivery.

    Time frame: Time of delivery

  7. Preeclampsia

    Medical records will be reviewed to determine whether a patient had a diagnosis of preeclampsia prior to delivery.

    Time frame: Time of delivery

07

Study locations

1 site
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Publications

  • Facco FL, Parker CB, Reddy UM, Silver RM, Koch MA, Louis JM, Basner RC, Chung JH, Nhan-Chang CL, Pien GW, Redline S, Grobman WA, Wing DA, Simhan HN, Haas DM, Mercer BM, Parry S, Mobley D, Hunter S, Saade GR, Schubert FP, Zee PC. Association Between Sleep-Disordered Breathing and Hypertensive Disorders of Pregnancy and Gestational Diabetes Mellitus. Obstet Gynecol. 2017 Jan;129(1):31-41. doi: 10.1097/AOG.0000000000001805. PubMed 27926645 ↗
  • Twedt R, Bradley M, Deiseroth D, Althouse A, Facco F. Sleep Duration and Blood Glucose Control in Women With Gestational Diabetes Mellitus. Obstet Gynecol. 2015 Aug;126(2):326-331. doi: 10.1097/AOG.0000000000000959. PubMed 26241422 ↗
  • Facco FL, Grobman WA, Kramer J, Ho KH, Zee PC. Self-reported short sleep duration and frequent snoring in pregnancy: impact on glucose metabolism. Am J Obstet Gynecol. 2010 Aug;203(2):142.e1-5. doi: 10.1016/j.ajog.2010.03.041. Epub 2010 May 26. PubMed 20510182 ↗
  • Qiu C, Enquobahrie D, Frederick IO, Abetew D, Williams MA. Glucose intolerance and gestational diabetes risk in relation to sleep duration and snoring during pregnancy: a pilot study. BMC Womens Health. 2010 May 14;10:17. doi: 10.1186/1472-6874-10-17. PubMed 20470416 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2019, 19 months.

Of 303 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's 19 months is below that.

Counting every sponsor, half of 306 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 29, 2017
StartActual
Nov 27, 2017
Primary completionActual
Jun 30, 2019
CompletionActual
Jun 30, 2019
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03266133
Responsible party
Roxanna Twedt (Graduate Medical Fellow, University of Pittsburgh) — Principal investigator
First posted
Aug 29, 2017
Start date
Nov 27, 2017
Primary completion
Jun 30, 2019
Completion
Jun 30, 2019
Last update
Aug 12, 2019

Study contacts

Roxanna Twedt, MD
principal investigator · Clinical Fellow, Division of Maternal-Fetal Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion